Chimeric Peptides Inhibiting NS3 Protease for Flaviviridae
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral treatments for Flaviviridae family viruses, such as HCV and DV, are limited in efficacy and face challenges like the generation of escape mutants, necessitating the development of new approaches to inhibit the NS3 protease effectively.
Innovation Solution
Design of chimerical peptides with a cell-penetrating segment and an NS3 protease inhibition segment that blocks the interaction between NS3 and its cofactors (NS2B or NS4A), stabilizing the inactive protease conformation and preventing viral replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral treatments (interferon monotherapy or interferon-ribavirin combined therapy) are used, then they provide some therapeutic effect, but they are limited in efficacy and generate escape mutants
Solution Approach 1:
The invention segments the antiviral mechanism by targeting specific proteolytic cleavage sites in the viral polyprotein. Instead of using broad-spectrum interferon therapy, the peptide inhibitors are designed to specifically block NS3 protease activity at defined molecular sites, thereby maintaining efficacy while reducing the selection pressure that leads to escape mutant generation.
Solution Approach 2:
The invention changes the therapeutic parameter from immunomodulation (interferon) to direct enzymatic inhibition (peptide inhibitors). By altering the mechanism of action to specifically target proteolytic cleavage, the treatment achieves higher efficacy with a different mode of action that does not favor escape mutant development through the same pathways as interferon-based therapies.
2Reliability
If peptide inhibitors targeting NS3 protease are designed, then they show enhanced specificity and reduced escape mutants, but they face challenges in cellular penetration and delivery
Solution Approach 1:
The invention creates composite peptide structures that combine the NS3 protease inhibitory sequence with cell-penetrating peptide sequences. This composite design integrates two functional elements: the antiviral inhibitory domain and the cellular delivery domain, allowing the single molecule to both enter cells efficiently and exert its specific inhibitory effect on NS3 protease.
Solution Approach 2:
The cell-penetrating peptide sequence acts as an intermediary that facilitates the delivery of the NS3 protease inhibitor into the cell. This intermediary element enables the specific inhibitory peptide to cross cellular barriers and reach its intracellular target, solving the delivery problem without compromising the specificity of the antiviral mechanism.
3Reliability
If the peptides are designed to block NS3-cofactor interaction, then they stabilize inactive protease conformation, but the molecular design complexity increases
Solution Approach 1:
The invention extracts the critical functional elements required for NS3 protease inhibition: the cofactor-binding interface and the catalytic active site. By designing peptides that specifically mimic or block these extracted functional elements, the invention achieves stable protease inhibition while maintaining a relatively simple peptide structure based on known viral sequence motifs.
Data Source
Figure 1A
Figure 1B~2B
Figure 3A~4B
AI summary
The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.